BioCentury | Aug 1, 2019
Distillery Therapeutics

Analogs of tumor-associated glycosphingolipids as cancer vaccines

...2019 doi:10.1016/j.chembiol.2019.03.018 CONTACT: H. Uri Saragovi, Jewish General Hospital, Montreal, Quebec; McGill University, Montreal, Quebec e-mail: uri.saragovi@mcgill.ca Sandi Wong Jewish General Hospital McGill...
BioCentury | Oct 18, 2018
Distillery Therapeutics

Neurology

...published Sept. 25, 2018 doi:10.1038/s41467-018-06449-x CONTACT: Andréa C. LeBlanc, Jewish General Hospital, Montreal, Quebec email: andrea.leblanc@mcgill.ca Jennie Walters Jewish General Hospital Amyloid...
BioCentury | May 3, 2017
Distillery Therapeutics

Cancer

...2017 doi:10.1038/ncomms14638 CONTACT: Josie Ursini-Siegel, Lady Davis Institute for Medical Research, Montreal, Quebec email: giuseppina.ursini-siegel@mcgill.ca Hongjiang Li Jewish General Hospital Programmed...
BioCentury | Aug 30, 2012
Distillery Techniques

Technology: Disease models

...W. et al. J. Neurosci.; published online Aug. 8, 2012; doi:10.1523/JNEUROSCI.6469-11.2012 Contact: Hyman M. Schipper, Jewish General Hospital...
BioCentury | Jun 27, 2011
Company News

Sunshine Biopharma, Jewish General Hospital deal

...molecule topoisomerase II (TOP2) inhibitor. Details were not disclosed. Sunshine Biopharma Inc. (OTCBB:SBFM), Montreal, Quebec Jewish General Hospital...
BioCentury | Sep 18, 2008
Cover Story

Dismantling cancer's immune defense

...microbiology, immunology and medicine at McGill University and director of the molecular oncology group at Jewish General Hospital...
...and Institutions Mentioned Bayer AG (Xetra:BAY), Leverkusen, Germany Jennerex Biotherapeutics Inc. , San Francisco, Calif. Jewish General Hospital...
BioCentury | Dec 5, 2005
Company News

BioVeris, Jewish General Hospital deal

...front and about $400,000 in research funding over three years. BioVeris Corp. (BIOV), Gaithersburg, Md. Jewish General Hospital...
Items per page:
1 - 7 of 7
BioCentury | Aug 1, 2019
Distillery Therapeutics

Analogs of tumor-associated glycosphingolipids as cancer vaccines

...2019 doi:10.1016/j.chembiol.2019.03.018 CONTACT: H. Uri Saragovi, Jewish General Hospital, Montreal, Quebec; McGill University, Montreal, Quebec e-mail: uri.saragovi@mcgill.ca Sandi Wong Jewish General Hospital McGill...
BioCentury | Oct 18, 2018
Distillery Therapeutics

Neurology

...published Sept. 25, 2018 doi:10.1038/s41467-018-06449-x CONTACT: Andréa C. LeBlanc, Jewish General Hospital, Montreal, Quebec email: andrea.leblanc@mcgill.ca Jennie Walters Jewish General Hospital Amyloid...
BioCentury | May 3, 2017
Distillery Therapeutics

Cancer

...2017 doi:10.1038/ncomms14638 CONTACT: Josie Ursini-Siegel, Lady Davis Institute for Medical Research, Montreal, Quebec email: giuseppina.ursini-siegel@mcgill.ca Hongjiang Li Jewish General Hospital Programmed...
BioCentury | Aug 30, 2012
Distillery Techniques

Technology: Disease models

...W. et al. J. Neurosci.; published online Aug. 8, 2012; doi:10.1523/JNEUROSCI.6469-11.2012 Contact: Hyman M. Schipper, Jewish General Hospital...
BioCentury | Jun 27, 2011
Company News

Sunshine Biopharma, Jewish General Hospital deal

...molecule topoisomerase II (TOP2) inhibitor. Details were not disclosed. Sunshine Biopharma Inc. (OTCBB:SBFM), Montreal, Quebec Jewish General Hospital...
BioCentury | Sep 18, 2008
Cover Story

Dismantling cancer's immune defense

...microbiology, immunology and medicine at McGill University and director of the molecular oncology group at Jewish General Hospital...
...and Institutions Mentioned Bayer AG (Xetra:BAY), Leverkusen, Germany Jennerex Biotherapeutics Inc. , San Francisco, Calif. Jewish General Hospital...
BioCentury | Dec 5, 2005
Company News

BioVeris, Jewish General Hospital deal

...front and about $400,000 in research funding over three years. BioVeris Corp. (BIOV), Gaithersburg, Md. Jewish General Hospital...
Items per page:
1 - 7 of 7